OptimizeRx Corp (OPRX) research
OptimizeRx Corp- Sector
- Healthcare
- Industry
- Health Information Services
- Last price
- $8.57
- As of
OptimizeRx Corp (OPRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-13.
As of . Source: SEC EDGAR filings for OPRX. Method and limitations.
Share the OPRX intelligence card
See the full OPRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for OPRX on one page. Preview it with sample data, then open it live with a free account.
Preview the OPRX dossierActive signals for OPRX
- highCONSENSUS_BUY
3 tracked funds increased OPRX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +365% to OPRX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +211% to OPRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1138% to OPRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +815% to OPRX (2026Q2)
FREE, NO ACCOUNT
Every signal on OPRX, as it fires
You are seeing 5 of 12 signals recorded on OPRX since 2026-05-26.
The five above landed across 2 days. The other 7 were recorded on 3 other days. 6 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in OPRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 68401U204 · 2026Q2 | $959K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 68401U204 · 2026Q2 | $904K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 68401U204 · 2026Q2 | $790K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 68401U204 · 2026Q2 | $451K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 68401U204 · 2026Q2 | $318K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, OPRX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
OPRX against its peers
OPRX's operating margin of 10.7% ranks in the 92nd percentile of 17 Health Information Services sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-01-31.
| Metric | OPRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 109M USD | 137M USD | 42 | 17 |
| Gross margin | 67.3% | 59.0% | 59 | 10 |
| Operating margin | 10.7% | -18.8% | 92 | 17 |
| Net margin | 4.7% | -35.5% | 81 | 17 |
| Return on equity | 4.0% | -30.0% | 75 | 17 |
| P / E | 31.7x | 20.2x | 75 | 5 |
Peers (19): LFMD, HCAT, AMWL, SY, RVRC, CCLD, CARL, TBRG, DRIO, NRC, VASO, WEAV, PHR, SOPH, ONMD, BEAT, CRVW, BFRG, SDGR. Left out: HYDTF (no annual filing), RNLXY (period gap), DGNOF (no annual filing), VRHI (no annual filing), RMHI (no annual filing), OHCFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (OPRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow OPRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to OPRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.